MTP

MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation. Further, it inhibits JAK2 signaling, rendering it useful for the study of oral squamous cell carcinoma [1].

Dirlotapide (CP742033) is an intestinal selective microsomal triglyceride transfer protein (MTP) inhibitor. It reduces body weight in diabetic dogs.Dirlotapide reduces food intake in a dose-dependent manner, possibly by increasing the release of peptide YY into the circulation.

Lomitapide (AEGR-733) is a small molecule inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme located in the lumen of the endoplasmic reticulum responsible for absorbing dietary lipids and transferring triglycerides onto apolipoprotein B (apo-B) in the assembly of very-low-density lipoprotein.

CP-319340 free base is an inhibitor of microsomal triglyceride transfer protein (MTP).

Implitapide is an inhibitor of microsomal triglyceride transfer protein (MTP).

PF-02575799 is an inhibitor of microsomal triglyceride transfer protein (MTP) (IC50: 0.77±0.29 nM).

Lomitapide Mesylate (BMS-201038 mesylate) is a methanesulfonic acid form of lomitapide, a small molecule inhibitor of microsomal triglyceride transfer protein.

KD-026 (SLx 4090), a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.

Mifamurtide is a drug against osteosarcoma, is an immunomodulator with antitumor effects.

Methional, the primary Strecker degradation product of methionine in foods, participates in oxidative coupling and alkyne hydroacylation reactions, and serves as a biosynthetic precursor for ethylene.

Mifamurtide protects mice against herpes simplex virus type 2. It also is a macrophage activator.

Mifamurtide sodium is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults. It was approved in Europe in March 2009.

BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques.

Granotapide is a microsomal triglyceride transfer protein (MTP) inhibitor that treats and rather prevents atherosclerosis, coronary artery disease, metabolic syndrome, obesity, diabetes mellitus, prediabetes mellitus, and hypertension.

Implitapide Racemate, the racemate of Implitapide, is an inhibitor of microsomal triglyceride transfer protein (MTP).

LAB687 (Compound 2a) is an inhibitor of microsomal triglyceride transfer protein (MTP) with an IC50 of 0.9 nM for inhibiting the secretion of apolipoprotein B (apoB) in HepG2 cells. Additionally, LAB687 acts as a Smoothened (Smo) antagonist, exhibiting IC50 values of 2.48 μM and 3.42 μM for mouse and human Smo receptors, respectively. This compound is effective in reducing triglyceride and low-density lipoprotein cholesterol (LDL-C) levels and in inhibiting the Hedgehog signaling pathway.

CP-346086 dihydrate is a potent, orally active inhibitor of microsomal triglyceride transfer protein (MTP), with an IC50 of 2.0 nM for both human and rodent MTP, effectively lowering plasma cholesterol and triglyceride levels in vivo.

CP-346086 is a highly potent and orally bioavailable inhibitor of microsomal triglyceride transfer protein (MTP), exhibiting an IC50 value of 2.0 nM against both human and rodent MTP. This compound effectively reduces plasma levels of cholesterol and triglycerides when administered in vivo.

PROTACMTP3 degrade-1 is a PROTAC degrader for MYC.

MTP3 ligand-1 is the MTP3 ligand component of PROTAC MTP3 degrade-1. PROTAC MTP3 degrade-1 functions as a PROTAC degrader for MYC.

MTP3 Ligand-linker Conjugate 1 is a compound formed by the combination of the MTP3 ligand and a linker. It is utilized in the synthesis of PROTAC[MTP3 degrade-1].

MTPPA (M 5011) is treating inflammation and pain.

Group II/group III metabotropic glutamate receptor antagonist

IMTPPE inhibits transcriptional activity and protein level of AR in C4-2 prostate cancer cells. It also inhibits AR-target gene expression.